Events

10th RSC-BMCS Fragment-based Drug Discovery Meeting

Event
10th RSC-BMCS Fragment-based Drug Discovery Meeting

Dates
Monday 14th September, 2026 – Wednesday 16th September, 2026

Place
Churchill College, Cambridge, UK

Important links
Social media hashtag – #Fragments26
To submit your Abstract, click here
To register, click here
To Sponsor, click here
Bursary application form, click here
First Announcement Poster, click here

Synopsis
The aim of the 10th RSC-BMCS Fragment-based Drug Discovery meeting will be to continue the focus on case studies in Fragment-based Drug Discovery that have delivered compounds to late stage medicinal chemistry, preclinical or clinical programmes. The Fragment series was started in 2007 and continues with this theme in having over three-quarters of the presentations focused on case studies. This will be complemented by technology progress in high concentration, NMR, SPR and X-ray screening.

Programme

Registration
14:00Opening Remarks
Alison Woolford, Astex Pharmaceuticals
14:00 - 15:50Session 1
Session Chair: Alison Woolford, Astex Pharmaceuticals
14:10 - 14:50Fragments from the GDB Chemical Space
Jean - Louis Reymond, ETH Switzerland,
14:50 - 15:20 Fragment-based discovery of potent and selective bridged-bicyclic CDK7 inhibitors
Charlie Griffiths-Jones, Astex
15:20 - 15:50 Why and how to dock fragments into RNA? - Synthon-based gigascale virtual screening against the SAM-I-riboswitch
Christian Kersten, Johannes Gutenberg-University
15:50 - 16:30Refreshments
16:30 - 17:30 Session 2
Session Chair: Chris Swain, Cambridge MedChem Consulting
16:30 - 17:00Tuning the open-close equilibrium of Cereblon with small molecules influences protein degradation
Suzanne O’Connor, University of Dundee
17:00 - 17:30 Ailsa Powell, XChem/DIAMOND
17:30 - 18:00Flash Posters
18:00 - 19:00Networking/Drinks in Marquee/Exhibition
19:00Buffet Dinner

Registration and Refreshments
09:00 - 10:40 Session 3
Session Chair: Emma Grant, GSK
09:00 - 09:40 Lysine targeting covalent fragment approaches against challenging drug targets
György M. Keserű, Hungarian Academy of Sciences
09:40 - 10:10 HARMing a Cryptic Pocket: AI Co-folding and FBDD to Deliver Covalent WRN Helicase Inhibitors
Geoffrey Smith, Boltz, previously at CHARM Therapeutics
10:10 - 10:40 Advancing BFL1-Selective Inhibitors: From Discovery to Optimization
Andrea Gohlke, AstraZeneca
10:40 - 11:20 Refreshments
11:20 - 12:20 Session 4
Chair: Gordon Saxty, NS-MC Consulting LTD
11:20 - 11:50A 25-year fragment journey – the good, the bad and the potential to put the I into AI approaches using lipophilic hotspots and water networks
Jonathan Mason, Design for Structure
11:50 - 12:20Flash Poster Presenters
12:20 - 14:30 Lunch and Poster Session / Exhibition
14:30 - 16:00 Session 5
Chair: Iva Lukac
14:30 - 15:00Fragment-based discovery of inhibitors of DHX8, an RNA helicase involved in mRNA splicing
Rob Van Montfort, ICR
15:00 - 15:30Expanding the Chemical Tractability of Human Proteome
Christopher Parker, Scripps Research Institute
15:30 - 16:00Leveraging fragments for orphan nuclear receptor ligand design
Daniel Merk, Ludwig-Maximilians-Universität
16:00 - 16:30Refreshments
16:30 - 17:30Session 6
Chair: Marianne Schimpl, AstraZeneca
16:30 - 17:00Towards Smarter FBDD: Harnessing Structure, AI and Physics
Paul Mortenson, Astex
17:00 - 17:30 Panel Discussion
17:30End of Session
18:30Conference Dinner (walk to St Johns)

Registration
09:30 - 11:30Session 7
Chair: Mary Wheldon, University of Dundee
09:30 - 10:00Fragment-based discovery of ligands targeting MITF, a bHLH transcription factor
Goran Malojcic, Novartis
10:00 - 10:30Fragment evolution via direct to biophysics: Identification of selective inhibitors of a CNS protease
Constance Agamasu, Vernalis
10:30 - 11:00Fast and Reliable NMR-Based Fragment Scoring for Drug Discovery
Ken Cameron, Cancer Research Horizons
11:00 - 11:30Late Breaker 1
11:30 - 13:30Lunch and Poster Session / Exhibition
13:30 - 15:30Session 8
Chair: Mike Hann
13:30 - 14:00Proteome-Scale Covalent Ligand Discovery Through Chemoproteomics and Machine Learning
Jacob Bush, GSK
14:00 - 14:30Crystallographic fragment screening against JUNO, a prominent non-hormonal contraception target
Martina Schaefer, Nuvisa
14:30 - 15:30Applying artificial and human intelligence to covalent fragment-based drug discovery (CFBDD)
Dan Erlanson, Frontier
15:30Closing Remarks
Mike Hann

Who should attend
This conference is suitable for scientists including chemists, biophysicists, structural biologists, etc., with either existing experience of fragments or wanting to learn about this exciting approach to drug discovery. This international meeting attracts delegates from the UK, several mainland European counties, as well as from the USA, Japan, China and South Korea.

Want to become a member?
To join the RSC in order to qualify for discounted registration fees at all RSC, please follow this RSC link.

Bursaries
The RSC-BMCS are offering a small number of bursaries to attend the meeting in person. Applications are open to PhD and post-doctoral applicants studying at academic institutions or non-profit institutions. Preference will be given to members of the RSC-BMCS. Bursary applications are also invited from RSC or EFMC members who are of working age, but currently unemployed, and from those who may have difficulty in funding themselves or whose organisations may have difficulty in funding their attendance. 

Please click here for the bursary application form. All applications should be sent to events@hg3.co.uk by Friday 24th July 2026.

Registration
Please click here to register.

RSC Member: £440
Non-Member: £540
RSC Student Member (undergraduate and post-graduate): £205
Student Non-Member (undergraduate and post-graduate): £270

Call for Abstracts
Abstract submission is now open, to submit your Abstract, click here.

Sponsorship/ Exhibitor Opportunities
Opportunities to sponsor or exhibit at the meeting are now open, please click here to book. If you have any questions around sponsorship or exhibition, please contact events@hg3.co.uk

Exhibition Package includes (£1,500)
– One stand personnel with access to all technical sessions
– Stand space: 3m wide x 2m deep
– Table: 240cm wide x 80cm deep, plus one chair
– Electrical and Wi-Fi access
– Logo and full promotional page in the delegate handbook (PDF version)
– Logo featured in the rolling slides displayed during breaks

Email blast includes (£250)
One promotional email sent to meeting delegates on your chosen date prior to the meeting. There are a number of dates available.

Poster listing
Poster listing will be open soon, check back for further details.

Organising Committee
Emma Grant, GSK
Mike Hann
Iva Lukac
Gordon Saxty, NS-MC Consulting LTD (Chair)
Marianne Schimpl, AstraZeneca
Chris Swain, Cambridge MedChem Consulting 
Mary Wheldon, University of Dundee (Treasurer)
Alison Woolford, Astex Pharmaceuticals

Secretariat Contact
Hg3 Conferences Ltd
+44 (0)1423 529333
E-mail`

Confirmed Exhibitors:
We are grateful to our confirmed exhibitors for their valued support

 


 

 

 

 

Confirmed Sponsors:
We are grateful to our confirmed sponsors for their valued support